SUN Pharmaceutical Industries LTD revenue defeated the street expectations by 9.4% year-on-June £13 851 crore. However, net profit of the drug manufacturer has decreased on exceptional items, including the cost of settlement in price antitrust lawsuits in the US and completion of clinical trials on one of its drugs.
The company has published net profit £2 279 Crore in Q1FY26, 20% compared to the previous year.
Healthy two -digit growth in his business in India and innovative drugs during the quarter increased his income and EBITDA margins. Drugmaker banned both segments to increase growth in FY26.
Also read | Sun Pharma, Lupine, Dr. Reddys remember products on the US market
Its modified net profit, with the exception of exceptional items, for Q1FY26 was £2,996 Crore, by 5.7%, Sun Pharma reported in the exchange on Thursday.
“Sun had a strong performance during the quarter, where overall growth reflects constant progress in all our markets. India continues to show strong dynamics and meaningfully contribute to our performance,” said Shanghvi, Chairman and CEO.
Sun Pharma and its subsidiary Taro Pharmaceuticals agreed to pay $ 200 million in the US at the beginning of this month to deal with a dispute over generic antitrust prices in the US. The company also announced that the study of its candidate SCD-044 for atopic dermatitis after the drug has not met primary objectives in phase 2 experiments.
Also read | Loss of Piramal Pharma tapers to RS82 Crore in June
Bloomberg’s vote with 14 brokers estimated that the income of the company is £13 699 crore and its profit after tax on £3 042 crore.
Sun Pharma reported EBITDA (income before interest, taxes, depreciation and amortization) £4 302 crore, by 19.2%, with margin expands to 31.1%.
The increase in the EBITDA margin was to improve the cost of raw materials as well as higher sales of its global specialized products and domestic branded formulations, the chief CFO of Jayashree Satagopan told investors in a profit call on Thursday evening.
Sun Pharma’s stock price settled 2% lower on £1700 on NSE on Thursday.
Robust indie, specialty growth
Sun Pharma’s home business has seen robust two -digit growth and maintained its dynamics. Sales of India formulation increased by 13.9% year -on -year £4 721 crore. Growth has been driven by an increase in volume and new launch, unlike the overall Indian pharmaceutical market, which is largely increasing on the basis of price increases.
The company has seen an increase in its global specialized or innovative sales of drugs and increased by 16.9% to $ 311 million. This segment represented 19.3% of its quarterly sales and increased the total US sales.
Also read | CCTV now mandatory in pharmacies to combat drug abuse
The company reported total US $ 473 million, by $ 1.4%. “This growth is powered by our innovative portfolio of medicinal products with all our growth products that contribute, including Ilumya, Cequa, Winlevi and Odomzo, but balanced by a decline in our generic business due to further competition in some products,” Proponents of excretion, which is still on the reimbursement, which is a supporter that it is still excluded, which is based on excretion, which is based on excretion, which is based on excretion, which is based on exclusion, which is based on exclusion. into the loss of excretion.
The US represented 29.3% of consolidated sales for quarter.
Sun Pharma has launched a drug for heavy alopecia area, Leqselvi, in the US during the quarter. “We are very encouraged by early results, we have seen good sensitivity with healthcare workers and patients, and we already have our initial commercial regulations,” Ascroft said.
Sun Pharma is preparing to launch Nonoxcyt cancer in the second half of FY26, the company said.
(Tagstotranslate) Sun Pharmaceutical Industries LTD (T) DrugMaker (T) Innovative drugs (T) Taro Pharmacy (T) Indian Pharmaceutical Market (T) Revlimide (T) Leqselvi (T) Healthcare workers (T) (T) in the US
